Thromboxane A2 receptor antagonism in man and rat by a sulphonylcyanoguanidine (BM-144) and a sulphonylurea (BM-500)

Journal of Pharmacy and Pharmacology

Volumn 51, Issue 6, 1999, Pages 695-701

  Masereel, B ^a   Damas, J ^b   Fontaine, J ^c   Lembege, M ^d   Lacan, F ^d   Nuhrich, A ^d   Delarge, J ^b   Pochet, L ^a   Dogne, J M ^b  

^a UNIVERSITY OF NAMUR   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ARACHIDONIC ACID; BM 144; BM 500; GUANIDINE DERIVATIVE; POTASSIUM CHLORIDE; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; SULFONYLCYANOGUANIDINE; SULFONYLUREA; SULOTROBAN; THROMBOCYTE RECEPTOR; THROMBOXANE A2 RECEPTOR; UNCLASSIFIED DRUG; HYDRAZINE DERIVATIVE; SULFONAMIDE; SULFONYLUREA DERIVATIVE; THROMBOXANE RECEPTOR;

ANIMAL TISSUE; AORTA; ARTERY DILATATION; ARTICLE; CONTROLLED STUDY; DIURESIS; DRUG DESIGN; DRUG POTENCY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RECEPTOR AFFINITY; SMOOTH MUSCLE CONTRACTION; STOMACH MUSCLE; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; IN VITRO STUDY; METABOLISM; THROMBOCYTE AGGREGATION; VASOCONSTRICTION; WISTAR RAT;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; HUMANS; HYDRAZINES; MALE; PLATELET AGGREGATION; RATS; RATS, WISTAR; RECEPTORS, THROMBOXANE; SULFONAMIDES; SULFONYLUREA COMPOUNDS; VASOCONSTRICTION;

EID: 0032587373     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357991772998     Document Type: Article

References (32)

1. Balant, L. (1981) Clinical pharmacokinetics of sulphonylurea hypoglycemic drugs. Clin. Pharmacokinet. 6: 215-241
2. 2. Nature (London) 315: 511-513
3. Born, G. V. R., Cross, M. J. (1963) The aggregation of blood platelets. J. Physiol. 168: 178-195
4. 2 can induce platelet aggregation in absence of secretion. Nature (London) 269: 66-69
5. Coleman, R. A., Sheldrich, R. L. G. (1989) Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors. Br. J. Pharmacol. 96: 688-692
6. 2 on some isolated smooth muscle preparations. Br. J. Pharmacol. 73: 773-778
7. Collington, E. W., Finch, H. (1990) Thromboxane synthase inhibitors and receptor antagonists. Annu. Rep. Med. Chem. 25: 99-108
8. Cozzi, P., Giordani, A., Menichincherin, M., Pillan, A., Pinciroli, V., Rossi, A., Tonani, R., Volpi, D., Tamburin, M., Ferrario, R., Fusar, D., Salvati, P. (1994) Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1 H-imidazol-1-yl)ethylidene]amino]-oxy]alkanoic acids. J. Med. Chem. 37: 3588-3604
9. Delaey, C., Van de Voorde, J. (1995) Prostanoid-induced contractions are blocked by sulfonylureas. Eur. J. Pharmacol. 280: 179-184
10. De Tullio, P., Pirotte, B., Lebrun, P., Fontaine, J., Dupont, L., Antoine, M. H., Ouedraogo, R., Khelili, S., Maggetto, C., Masereel, B., Diouf, O., Podona, T., Delarge, J. (1996) 3-and 4-substituted 4 H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium-channel openers: synthesis, pharmaco-logical evaluation, and structure-activity relationships. J. Med. Chem. 39: 937-948
11. 2-prostaglandin endoperoxide receptor activation in vivo. J. Clin. Invest. 77: 496-502
12. Friedel, H. A., Buckley, M. M. T. (1991) Torasemide. A review of its pharmacological and therapeutic potential. Drugs 41: 81-103
13. 2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation. J. Pharmacol. Exp. Ther. 258: 74-81
14. Gresele, P., Deckmyn, H., Arnout, J., Lemmens, J., Janssens, W., Vermylen, J. (1984) BM 13177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet 5: 991-994
15. 2-receptors in human platelets. J. Pharmacol. Exp. Ther. 245: 786-792
16. Jakubowski, J. A., Smith, G. F., Sail, D. J. (1992) Future anti-thrombotic therapy. Annu. Rep. Med. Chem. 27: 99-108
17. Krauss, A. H., Woodward, D. L., Gibson, L. L., Protzman, C. E., Williams, L. S., Burk, R. M., Roof, M. B., Abbas, F., Marshall, K., Senior, J. (1996) Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha. Br. J. Pharmacol. 117: 1171-1180
18. + cotransport system as a marker of antihypertensive activity of new torasemide derivatives. Eur. J. Pharmacol. 219: 385-394
19. Masereel, B., Schynts, M., Krzesinski, J. M., Pirotte, B., Rorive, G., Delarge, J. (1993) A sulfonylthiourea (BM 20) related to torasemide, a new loop diuretic with relative potassium-sparing properties. J. Pharm. Pharmacol. 45: 720-724
20. + co-transporter. Eur. J. Med. Chem. 29: 527-535
21. Masereel, B., Laeckmann, D., Dupont, L., Liégeois, J. F., Pirotte, B., de Tullio, P., Delarge, J. (1995) Synthesis and pharmacology of pyrid-3-yl sulfonylcyanoguanidines as diuretics. Eur. J. Med. Chem. 30: 343-351
22. Masereel, B., Lambert, D. M., Dogné, J. M., Poupaert, J. H., Delarge, J. (1997) Anticonvulsant activity of pyrid-3-yl-sulphonyl urea and thiourea. Epilepsia 38: 334-337
23. Masereel, B., Wouters, J., Pochet, L., Lambert, D. M. (1998) Design, synthesis and anticonvulsant activity of 1-(pyrid-3-ylsulphonamido)-2-nitroethylenes. J. Med. Chem. 41: 3239-3244
24. Nuhrich, A., Varache-Lembège, M., Lacan, F., Devaux, G. (1996) Use of infrared spectroscopy in monitoring a new method for the preparation of sulotroban, an antithrombotic drug. J. Chem. Educ. 73: 1185-1189
25. 2 formation (1). N. Engl. J. Med. 319: 689-698
26. 2 formation (2). N. Engl. J. Med. 319: 761-767
27. Ogletree, M. L., Harris, D. N., Greenberg, R., Haslanger, M. F., Nakane, M. (1985) Pharmacological actions of SQ-29,548, a novel selective thromboxane antagonist. J. Pharmacol. Exp. Ther. 234: 435-441
28. 2 receptor antagonists and synthase inhibitors. J. Med. Chem. 37: 26-39
29. 3H]BAY U 3405 to washed human platelets and platelets membranes. Biochem. Pharmacol. 44: 495-503
30. 2-induced contraction in the isolated canine coronary artery. Prostaglandins Leukot. Fatty Acids 45: 121-124
31. Vane, J. R. (1957) A sensitive method for the assay of 5-hydroxytryptamine. Br. J. Pharmacol. 12: 344-350
32. 2 receptor and analysis of the receptor-ligand interaction. J. Med. Chem. 36: 820-825